ABLE | Home use, affordable and lightweight exoskeleton for people with lower-limb paralysis

Summary
People with lower-limb paralysis could walk again if they had a robotic exoskeleton to restore the leg movements affected by the injury. However, current devices are expensive (cost about 100 k€), heavy and require trained professional supervision. Therefore, they are only found in large hospitals and rehabilitation centers, and are out of the reach of the patient.

ABLE Human Motion is a medical device spin-off from Universitat Politècnica de Catalunya (UPC) that is developing and will commercialize robotic exoskeletons to enhance their mobility and independence. ABLE’s vision is to build a world where everybody has the possibility to move independently, with that aim we plan the launch of ABLE: the first home use, affordable and lightweight exoskeleton that restores the ability to walk of people with lower-limb paralysis in a natural and intuitive way. It is based on an electric actuator that flexes and extends the leg mimicking human natural movement, and an inertial sensor that together with dedicated algorithms detects the user’s intention to make the step forward. This patented and disruptive system to assist walking helps palliating health issues caused by sedentary lifestyle while boosting self-confidence and independence.

So far our newly established company has been awarded as an innovative technology to improve healthcare by CaixaImpulse and EIT Health. We have been selected among the 5 most promising medtech start-ups by MassMEDIC (Boston, USA). The team has also won the acceleration programs organized by Richi Foundation and CIMIT, the most successful health accelerator in the world. This has allowed us to validate the product-market fit with more than 150 stakeholders, establishing a viable business model and a go-to-market plan.

The project is currently at Technology Readiness Level (TRL) between 6 and 7, and should reach TRL9 within an 18-month timeframe.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/855081
Start date: 01-03-2019
End date: 31-08-2019
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

People with lower-limb paralysis could walk again if they had a robotic exoskeleton to restore the leg movements affected by the injury. However, current devices are expensive (cost about 100 k€), heavy and require trained professional supervision. Therefore, they are only found in large hospitals and rehabilitation centers, and are out of the reach of the patient.

ABLE Human Motion is a medical device spin-off from Universitat Politècnica de Catalunya (UPC) that is developing and will commercialize robotic exoskeletons to enhance their mobility and independence. ABLE’s vision is to build a world where everybody has the possibility to move independently, with that aim we plan the launch of ABLE: the first home use, affordable and lightweight exoskeleton that restores the ability to walk of people with lower-limb paralysis in a natural and intuitive way. It is based on an electric actuator that flexes and extends the leg mimicking human natural movement, and an inertial sensor that together with dedicated algorithms detects the user’s intention to make the step forward. This patented and disruptive system to assist walking helps palliating health issues caused by sedentary lifestyle while boosting self-confidence and independence.

So far our newly established company has been awarded as an innovative technology to improve healthcare by CaixaImpulse and EIT Health. We have been selected among the 5 most promising medtech start-ups by MassMEDIC (Boston, USA). The team has also won the acceleration programs organized by Richi Foundation and CIMIT, the most successful health accelerator in the world. This has allowed us to validate the product-market fit with more than 150 stakeholders, establishing a viable business model and a go-to-market plan.

The project is currently at Technology Readiness Level (TRL) between 6 and 7, and should reach TRL9 within an 18-month timeframe.

Status

CLOSED

Call topic

EIC-SMEInst-2018-2020

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.0. INDUSTRIAL LEADERSHIP - Innovation In SMEs - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.0. Cross-cutting call topics
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1